ArticleInternational journal of environmental research and public health2019
Impact of OM-85 Given during Two Consecutive Years to Children with a History of Recurrent Respiratory Tract Infections: A Retrospective Study.
Article in International journal of environmental research and public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Efficacy and safety of OM-85 in paediatric recurrent respiratory tract infections which could have a possible protective effect on COVID-19 pandemic: A meta-analysis.International journal of clinical practice · 2021Pooled it
- OM-85 BV for primary prevention of recurrent airway infections: a pilot randomized, double-blind, placebo-controlled study.Einstein (Sao Paulo, Brazil) · 2020Trial
- A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections.Journal of translational medicine · 2019Trial
- Oral Bacterial Lysate OM-85: Advances in Pharmacology and Therapeutics.Drug design, development and therapy · 2024Review
- Expert consensus on the role of OM-85 in the management of recurrent respiratory infections: A Delphi study.Human vaccines & immunotherapeutics · 2022Article
- Prevention of recurrent respiratory infections : Inter-society Consensus.Italian journal of pediatrics · 2021Article
- Immunological Aspects of Diagnosis and Management of Childhood Tuberculosis.Infection and drug resistance · 2021Review
- Prevention of New Respiratory Episodes in Children with Recurrent Respiratory Infections: An Expert Consensus Statement.Microorganisms · 2020Review
- Paediatric Recurrent Ear, Nose and Throat Infections and Complications: Can We Do More?Infectious diseases and therapy · 2020Review
- Global Community Child Health.International journal of environmental research and public health · 2020Article
- Dysbiosis of the gut and lung microbiome has a role in asthma.Seminars in immunopathology · 2020Review
- Dynamic Interplay Between Microbiota and Mucosal Immunity in Early Shaping of Asthma and its Implication for the COVID-19 Pandemic.Journal of asthma and allergy · 2020Review
- Bacterial Lysates as Immunotherapies for Respiratory Infections: Methods of Preparation.Frontiers in bioengineering and biotechnology · 2020Review
- Vaccination against Paediatric Respiratory Pathogens.Vaccines · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In otherwise healthy infants and young children, respiratory tract infections (RTIs) are extremely common. Clinical data have shown that OM-85 could prevent respiratory recurrences in children. However, further studies are needed to explore the true importance of OM-85 in clinical practice. In addition, an unsolved problem is the efficacy of OM-85 when it is administered for two consecutive years. Moreover, another open question is the safety of OM-85 when co-administered with the influenza vaccine. In order to solve these unanswered issues, 200 children aged three to six years with a history of recurrent RTIs, defined as at least six documented episodes of acute RTI in a single year, who had received OM-85 (Broncho-Vaxom
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.